Abstract Number: PB2407
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » VTE Treatment
Background: The recommended dose of edoxaban for venous thromboembolism (VTE) treatment is 60 mg daily, or 30 mg daily in particular clinical conditions. No real-life data are currently available about its use in long-term treatment.
Aims: To assess the efficacy and safety of edoxaban for long-term VTE treatment in real-life setting.
Methods: Prospective data from VTE patients receiving edoxaban 60 mg or 30 mg daily included in 204 centers participating in the RIETE registry from October 2015 to November 2019, aimed to validate the benefit of using different dosages. Outcome of the study was the cumulative rate of the composite of VTE recurrences or major bleeding in patients with or without criteria for dose reduction. Multivariable analysis was performed to identify independent predictors for the composite outcome.
Results: 562 patients received edoxaban for long-term therapy. Most (94%) of the 416 patients not meeting criteria for dose reduction received edoxaban 60 mg daily, and 92 patients meeting criteria (63%) received 30 mg daily. During treatment, 2 patients developed recurrent VTE, 6 had major bleeding and 9 died (fatal bleeding 2). Among patients not meeting criteria for dose reduction, those receiving 30 mg daily had a higher rate of the composite event (hazard ratio [HR] 8.37; 95%CI 1.12-42.4) and a significant higher mortality rate (HR 31.1; 95%CI 4.63-262) than those receiving 60 mg. On multivariable analysis, only patients with cancer or chronic heart failure were at increased risk for the composite event. Among patients meeting criteria for dose reduction, those receiving 60 mg daily had no VTE recurrences, no major bleeding, and a non-significantly higher mortality rate (HR 5.04;95%CI 0.54-133) than those receiving 30 mg daily.
Conclusions: Edoxaban seems to be effective and safe for long-term VTE treatment in real-life. The criteria for dose reduction should be reformulated to include other parameters.
To cite this abstract in AMA style:
Camporese G, Simioni P, Di Micco P, Fernández-Capitán C, Rivas A, Font C, Sahuquillo JC, Villares P, Prandoni P, Monreal M. Edoxaban for the Long-Term Therapy of Venous Thromboembolism in Real-Life RIETE Registry [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/edoxaban-for-the-long-term-therapy-of-venous-thromboembolism-in-real-life-riete-registry/. Accessed April 18, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/edoxaban-for-the-long-term-therapy-of-venous-thromboembolism-in-real-life-riete-registry/